Show simple item record

dc.contributor.authorLambros, MB
dc.contributor.authorSeed, G
dc.contributor.authorSumanasuriya, S
dc.contributor.authorGil, V
dc.contributor.authorCrespo, M
dc.contributor.authorFontes, M
dc.contributor.authorChandler, R
dc.contributor.authorMehra, N
dc.contributor.authorFowler, G
dc.contributor.authorEbbs, B
dc.contributor.authorFlohr, P
dc.contributor.authorMiranda, S
dc.contributor.authorYuan, W
dc.contributor.authorMackay, A
dc.contributor.authorFerreira, A
dc.contributor.authorPereira, R
dc.contributor.authorBertan, C
dc.contributor.authorFigueiredo, I
dc.contributor.authorRiisnaes, R
dc.contributor.authorRodrigues, DN
dc.contributor.authorSharp, A
dc.contributor.authorGoodall, J
dc.contributor.authorBoysen, G
dc.contributor.authorCarreira, S
dc.contributor.authorBianchini, D
dc.contributor.authorRescigno, P
dc.contributor.authorZafeiriou, Z
dc.contributor.authorHunt, J
dc.contributor.authorMoloney, D
dc.contributor.authorHamilton, L
dc.contributor.authorNeves, RP
dc.contributor.authorSwennenhuis, J
dc.contributor.authorAndree, K
dc.contributor.authorStoecklein, NH
dc.contributor.authorTerstappen, LWMM
dc.contributor.authorde Bono, JS
dc.date.accessioned2019-04-24T08:33:47Z
dc.date.issued2018-11-15
dc.identifier.citationClinical cancer research : an official journal of the American Association for Cancer Research, 2018, 24 (22), pp. 5635 - 5644
dc.identifier.issn1078-0432
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3199
dc.identifier.eissn1557-3265
dc.identifier.doi10.1158/1078-0432.ccr-18-0862
dc.description.abstractPurpose: Circulating tumor cells (CTCs) have clinical relevance, but their study has been limited by their low frequency.Experimental Design: We evaluated liquid biopsies by apheresis to increase CTC yield from patients suffering from metastatic prostate cancer, allow precise gene copy-number calls, and study disease heterogeneity.Results: Apheresis was well tolerated and allowed the separation of large numbers of CTCs; the average CTC yield from 7.5 mL of peripheral blood was 167 CTCs, whereas the average CTC yield per apheresis (mean volume: 59.5 mL) was 12,546 CTCs. Purified single CTCs could be isolated from apheresis product by FACS sorting; copy-number aberration (CNA) profiles of 185 single CTCs from 14 patients revealed the genomic landscape of lethal prostate cancer and identified complex intrapatient, intercell, genomic heterogeneity missed on bulk biopsy analyses.Conclusions: Apheresis facilitated the capture of large numbers of CTCs noninvasively with minimal morbidity and allowed the deconvolution of intrapatient heterogeneity and clonal evolution. Clin Cancer Res; 24(22); 5635-44. ©2018 AACR.
dc.formatPrint-Electronic
dc.format.extent5635 - 5644
dc.languageeng
dc.language.isoeng
dc.publisherAMER ASSOC CANCER RESEARCH
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectProstatic Neoplasms
dc.subjectCell Transformation, Neoplastic
dc.subjectBlood Component Removal
dc.subjectCell Count
dc.subjectCell Separation
dc.subjectIn Situ Hybridization, Fluorescence
dc.subjectGenetic Heterogeneity
dc.subjectMale
dc.subjectNeoplastic Cells, Circulating
dc.subjectComparative Genomic Hybridization
dc.subjectSingle-Cell Analysis
dc.subjectHigh-Throughput Nucleotide Sequencing
dc.subjectBiomarkers, Tumor
dc.subjectLiquid Biopsy
dc.titleSingle-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis.
dc.typeJournal Article
dcterms.dateAccepted2018-07-18
rioxxterms.versionofrecord10.1158/1078-0432.ccr-18-0862
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2018-11
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfClinical cancer research : an official journal of the American Association for Cancer Research
pubs.issue22
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Cancer Biomarkers
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Glioma Team
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Cancer Biomarkers
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Translational Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Glioma Team
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/16/17 Starting Cohort
pubs.organisational-group/ICR/Students/PhD and MPhil/18/19 Starting Cohort
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Cancer Biomarkers
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Glioma Team
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Cancer Biomarkers
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Translational Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Glioma Team
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/16/17 Starting Cohort
pubs.organisational-group/ICR/Students/PhD and MPhil/18/19 Starting Cohort
pubs.publication-statusPublished
pubs.volume24
pubs.embargo.termsNot known
icr.researchteamCancer Biomarkers
icr.researchteamProstate Cancer Targeted Therapy Group
icr.researchteamTranslational Therapeutics
icr.researchteamGlioma Team
dc.contributor.icrauthorSeed, George
dc.contributor.icrauthorSumanasuriya, Semini
dc.contributor.icrauthorMiranda, Susana
dc.contributor.icrauthorMackay, Alan
dc.contributor.icrauthorPereira, Ana Rita
dc.contributor.icrauthorSharp, Adam
dc.contributor.icrauthorGoodall, Jane
dc.contributor.icrauthorCarreira, Suzanne
dc.contributor.icrauthorRescigno, Pasquale
dc.contributor.icrauthorDe Bono, Johann


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0